Dissecting BRCA1-PALB2 Activity in DNA Repair and Development

剖析 BRCA1-PALB2 在 DNA 修复和发育中的活性

基本信息

  • 批准号:
    10664883
  • 负责人:
  • 金额:
    $ 38.66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-05 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The BRCA1 and PALB2 proteins directly heterodimerize through their respective coiled-coil (CC) domains, facilitating the formation of a larger BRCA1-PALB2-BRCA2-RAD51 complex that is required for RAD51 filament formation. Currently, little is known about the structural basis of the BRCA1-PALB2 interaction, including the residue alignment and orientation of physically interacting -helices. Elucidating CC molecular interactions is critical for understanding how mutations found in patients disrupt peptide interactions and promote disease. Protein CC domains are capable of mediating interactions with several CC domain containing partners. However, BRCA1 and PALB2 form the only known interaction that is mediated by their respective CC domains. Whether BRCA1 and PALB2 CC domains exclusively interact with one another, or if there are additional CC interactions and functions is unknown. Our laboratory has developed novel BRCA1 and PALB2 CC domain mutant mouse models to investigate the significance of this interaction in DNA repair and organismal health. We have also purified CC peptides so that biochemical assays can be performed assessing the effects of mutations on complex interactions and activity. The only known function of BRCA1 and PALB2 CC domains is to interact with one another, thus, BRCA1CC and PALB2CC homozygous mice might be expected to have identical phenotypes. However, while BRCA1CC mice are born at sub-Mendelian ratios and neo-natal mice demonstrate a range of developmental defects, PALB2CC homozygosity resulted in early embryonic lethality. Because BRCA1CC and PALB2CC mice have distinct phenotypes, we hypothesize that CC domains facilitate protein interactions beyond the BRCA1-PALB2 heterodimer that promote DNA repair and embryonic development. We will address the following Specific Aims: 1) Determine biochemical CC interactions and activity; 2) Uncover DNA repair and developmental defects in CC mutant mice; and 3) Elucidate mechanisms of BRCA1-PALB2 complex recruitment to DNA breaks. Collectively, the proposed experiments will yield new insight into the mechanism by which the BRCA1-PALB2 complex protects from genome instability.
项目摘要 BRCA 1和PALB 2蛋白通过它们各自的卷曲螺旋(CC)结构域直接异二聚化, 促进形成RAD 51细丝所需的更大的BRCA 1-PALB 2-BRCA 2-RAD 51复合物 阵目前,对BRCA 1-PALB 2相互作用的结构基础知之甚少,包括 物理相互作用的β-螺旋的残基排列和取向。阐明CC分子相互作用是 对于了解患者中发现的突变如何破坏肽相互作用并促进疾病至关重要。 蛋白质CC结构域能够介导与几个含有CC结构域的配偶体的相互作用。然而,在这方面, BRCA 1和PALB 2形成了唯一已知的由它们各自的CC结构域介导的相互作用。是否 BRCA 1和PALB 2 CC结构域仅相互作用,或者如果存在额外的CC相互作用, 功能不明。本实验室开发了新型BRCA 1和PALB 2 CC结构域突变小鼠 模型来研究这种相互作用在DNA修复和生物体健康中的意义。我们还 纯化的CC肽,以便可以进行生物化学测定,评估突变对复合物的影响。 互动和活动。BRCA 1和PALB 2 CC结构域的唯一已知功能是与一个 因此,另一种BRCA 1CC和PALB 2CC纯合子小鼠可能具有相同的表型。 然而,尽管BRCA 1CC小鼠以亚孟德尔比率出生,新生小鼠表现出一系列的 发育缺陷,PALB 2CC纯合性导致早期胚胎死亡。因为BRCA 1CC和 PALB 2CC小鼠具有不同的表型,我们假设CC结构域促进蛋白质相互作用, 促进DNA修复和胚胎发育BRCA 1-PALB 2异二聚体。我们将解决 以下具体目标:1)确定生物化学CC相互作用和活性; 2)揭示DNA修复, CC突变小鼠的发育缺陷;和3)阐明BRCA 1-PALB 2复合物募集的机制 DNA断裂总的来说,所提出的实验将产生新的见解的机制, BRCA 1-PALB 2复合物保护基因组不稳定性。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
  • DOI:
    10.1016/j.molcel.2021.06.011
  • 发表时间:
    2021-08-05
  • 期刊:
  • 影响因子:
    16
  • 作者:
    Cong, Ke;Peng, Min;Kousholt, Arne Nedergaard;Lee, Wei Ting C.;Lee, Silviana;Nayak, Sumeet;Krais, John;VanderVere-Carozza, Pamela S.;Pawelczak, Katherine S.;Calvo, Jennifer;Panzarino, Nicholas J.;Turchi, John J.;Johnson, Neil;Jonkers, Jos;Rothenberg, Eli;Cantor, Sharon B.
  • 通讯作者:
    Cantor, Sharon B.
Brca1 mutations in the coiled-coil domain impede Rad51 loading on DNA and mouse development.
卷曲螺旋结构域中的 Brca1 突变阻碍了 Rad51 在 DNA 上的加载和小鼠发育。
  • DOI:
    10.1080/23723556.2020.1786345
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Krais,JJ;Johnson,N
  • 通讯作者:
    Johnson,N
BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
  • DOI:
    10.1158/0008-5472.can-20-1830
  • 发表时间:
    2020-11-01
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Krais JJ;Johnson N
  • 通讯作者:
    Johnson N
RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage.
  • DOI:
    10.1038/s41467-021-25346-4
  • 发表时间:
    2021-08-18
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
    Krais JJ;Wang Y;Patel P;Basu J;Bernhardy AJ;Johnson N
  • 通讯作者:
    Johnson N
BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
BRCA1 单倍体不足被 RNF168 介导的染色质泛素化掩盖。
  • DOI:
    10.1016/j.molcel.2018.12.010
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    16
  • 作者:
    Zong,Dali;Adam,Salomé;Wang,Yifan;Sasanuma,Hiroyuki;Callén,Elsa;Murga,Matilde;Day,Amanda;Kruhlak,MichaelJ;Wong,Nancy;Munro,Meagan;RayChaudhuri,Arnab;Karim,Baktiar;Xia,Bing;Takeda,Shunichi;Johnson,Neil;Durocher,Daniel;Nusse
  • 通讯作者:
    Nusse
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Neil Johnson其他文献

Neil Johnson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Neil Johnson', 18)}}的其他基金

Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer
评估 DNA 聚合酶 θ 作为 BRCA1 突变癌症的治疗靶点
  • 批准号:
    10446399
  • 财政年份:
    2022
  • 资助金额:
    $ 38.66万
  • 项目类别:
Assessing DNA Polymerase Theta as a Therapeutic Target in BRCA1 Mutant Cancer
评估 DNA 聚合酶 Theta 作为 BRCA1 突变癌症的治疗靶点
  • 批准号:
    10884036
  • 财政年份:
    2022
  • 资助金额:
    $ 38.66万
  • 项目类别:
Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer
评估 DNA 聚合酶 θ 作为 BRCA1 突变癌症的治疗靶点
  • 批准号:
    10579323
  • 财政年份:
    2022
  • 资助金额:
    $ 38.66万
  • 项目类别:
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development
剖析 BRCA1-PALB2 在 DNA 修复和发育中的活性
  • 批准号:
    10229611
  • 财政年份:
    2020
  • 资助金额:
    $ 38.66万
  • 项目类别:
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development
剖析 BRCA1-PALB2 在 DNA 修复和发育中的活性
  • 批准号:
    10453625
  • 财政年份:
    2020
  • 资助金额:
    $ 38.66万
  • 项目类别:
The role of microhomology-mediated end joining in Fanconi anemia pathogenesis
微同源介导的末端连接在范可尼贫血发病机制中的作用
  • 批准号:
    10580006
  • 财政年份:
    2020
  • 资助金额:
    $ 38.66万
  • 项目类别:
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development
剖析 BRCA1-PALB2 在 DNA 修复和发育中的活性
  • 批准号:
    10388570
  • 财政年份:
    2020
  • 资助金额:
    $ 38.66万
  • 项目类别:
The role of microhomology-mediated end joining in Fanconi anemia pathogenesis
微同源介导的末端连接在范可尼贫血发病机制中的作用
  • 批准号:
    10367981
  • 财政年份:
    2020
  • 资助金额:
    $ 38.66万
  • 项目类别:
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers
促进 BRCA1 突变癌症同源重组的补偿机制
  • 批准号:
    10242152
  • 财政年份:
    2019
  • 资助金额:
    $ 38.66万
  • 项目类别:
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers
促进 BRCA1 突变癌症同源重组的补偿机制
  • 批准号:
    9762056
  • 财政年份:
    2019
  • 资助金额:
    $ 38.66万
  • 项目类别:

相似海外基金

Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
  • 批准号:
    BB/Y006380/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.66万
  • 项目类别:
    Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
  • 批准号:
    24K17112
  • 财政年份:
    2024
  • 资助金额:
    $ 38.66万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
  • 批准号:
    23K04668
  • 财政年份:
    2023
  • 资助金额:
    $ 38.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
  • 批准号:
    23K06918
  • 财政年份:
    2023
  • 资助金额:
    $ 38.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
  • 批准号:
    23K05758
  • 财政年份:
    2023
  • 资助金额:
    $ 38.66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
  • 批准号:
    2888395
  • 财政年份:
    2023
  • 资助金额:
    $ 38.66万
  • 项目类别:
    Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
  • 批准号:
    2300890
  • 财政年份:
    2023
  • 资助金额:
    $ 38.66万
  • 项目类别:
    Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 38.66万
  • 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
  • 批准号:
    10728925
  • 财政年份:
    2023
  • 资助金额:
    $ 38.66万
  • 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
  • 批准号:
    10757309
  • 财政年份:
    2023
  • 资助金额:
    $ 38.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了